Sample Pages/Table of Contents
Publication Details
BioWorld Top 25 Biotechnology Drugs Report 2008
Product Code: S08416
Published: May 2008
Pages: 250
Format: Print and PDF
Price: $599* (plus $17.95 s&h)
Publisher
BioWorld Today
Guarantee
You may review this product risk-free for 30 days. If you do not wish to keep the product, please return the product, together with the invoice marked
"Cancel" to AHC at 4401 Freidrich Lane, Suite 205 Austin, TX 78744-1849 U.S.A. Shipping and handling charges for returned items are the responsibility of the customer. If you have any questions or concerns you may contact us at 800-688-2421 or 404-262-5476 or by e-mailing customerservice@ahcmedia.com.
|
 |
BioWorld Top 25 Biotechnology Drugs Report 2008
This expertly written report effectively evaluates the biotechnology and pharma drug market on the grounds of innovation, growth and FDA approvals and provides a critical analysis of both industries principal products, as well as the active and evolving biotech/pharma relationship.
The biotechnology drug market is doing well, but big pharma s sudden interest in big molecules is turning out to be the predominant factor determining the future of the biotech therapeutics industry. This report analyzes that dynamic, in addition to other issues, such as regulatory, R&D, drug pricing, biogenerics and even financing matters.
BioWorld Today s newest edition of the
Top 25 Biotechnology Drugs Report delivers the history, topical business-in-progress and the prospective outlook of the rapidly maturing biotechnology market that finds itself navigating in a first-of-its-kind market environment for any industry: Big pharma on one side and biogenerics competition on the other side. Anyone involved or interested in this unique market needs the comprehensive and relevant data and analysis that the
Top 25 Biotechnology Drugs Report offers.
Highlights of coverage include:
- Revenue rankings of each drug
- Indications
- Disease description & statistics
- Chronology of development through approval
- Patent expirations
- Competing drugs on the market and in development
- Secondary indications in development
- Partnerships involved in the drug
- Projection of the drug's short-term future
- Prevailing trends in drug development
- Evolving pharma/biotech relationships
- Biosimilars impact
These drug profiles span a wide range of disease indications, including cancer, diabetes, infectious diseases and blood disorders. Chart- and table-focused sections of the report also lend themselves nicely as supporting data for company reports and presentations.
Charts and tables include:
- All biotech drugs approved over the last 20 years
- Comparative values of biotech and pharma markets
- Revenue generated by the top 100 biotech and pharma drugs
- Leading biotech pipeline candidates
By combining more than 250 pages of drug history, product life-cycle analysis, industry trends and company data, the
BioWorld Top 25 Biotechnology Drugs Report provides the perfect resource for understanding the current state and future of the biotechnology drug market.
How To Order:
Order our BioWorld Top 25 Biotechnology Drugs Report risk-free for 30 days for only $599 (plus $17.95 s&h) by choosing an option below. Or call us at 1-800-688-2421 or 1-404-262-5476 and
mention priority code S08416-I5973.
|
